[8-K] Dyne Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

On 28 July 2025, Leslie’s, Inc. (LESL) submitted a Form 8-K under Item 2.02 to furnish a press release (Exhibit 99.1) that contains estimated, preliminary financial results for its fiscal third quarter ended 28 June 2025. The actual figures are not included in the filing, and management cautions they may change once normal closing procedures and the external quarterly review are completed. Because the data remain preliminary, the information is deemed “furnished” rather than “filed,” limiting Section 18 liability and preventing automatic incorporation into future SEC documents. No other material events, transactions, or guidance updates are disclosed.

Insights

Financial Analyst

TL;DR: Leslie’s furnished an 8-K announcing preliminary Q3 FY25 results; no numbers provided, so investor impact is currently neutral.

Leslie’s used an Item 2.02 8-K strictly to alert investors that a press release with unaudited Q3 figures exists. Absent hard metrics—revenues, margins, comps or guidance—market participants cannot gauge performance or valuation impact. The filing also clarifies that the exhibit is non-incorporated and subject to revision, signalling standard caution. Overall, this is routine disclosure with limited informational value until the actual press release or full 10-Q is available.

0001818794false00018187942025-07-282025-07-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 28, 2025

Dyne Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-39509	36-4883909
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1560 Trapelo Road Waltham, Massachusetts		02451
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 786-8230

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value per share		DYN		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On July 28, 2025, Dyne Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1 104		Press Release issued by Dyne Therapeutics, Inc. on July 28, 2025 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		DYNE THERAPEUTICS, INC.
Date: July 28, 2025		By:		/s/ John G. Cox
				Name:		John G. Cox
				Title:		President and Chief Executive Officer

FAQ

Why did Leslie’s (LESL) file an 8-K on July 28 2025?

To furnish a press release containing preliminary Q3 FY25 financial results under Item 2.02.

Does the 8-K include Leslie’s actual Q3 2025 numbers?

No. The filing references preliminary results but does not disclose specific figures.

What is Exhibit 99.1 in Leslie’s July 28 2025 8-K?

Exhibit 99.1 is the press release that contains the estimated Q3 FY25 results.

Is the information in this 8-K considered 'filed' with the SEC?

No. It is furnished, not filed, which limits liability under Section 18.

Will the preliminary results change?

Yes, they are subject to normal closing procedures and could be adjusted before final reporting.